Publications by authors named "B Corront"
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.
Br J Haematol
April 2023
Low baseline NK-cell counts (NKCCs) in patients with diffuse large B-cell lymphoma (DLBCL) are associated with a poor prognosis. The REMARC phase III trial (NCT01122472) showed that lenalidomide maintenance prolonged PFS in rituximab-chemotherapy responders. We conducted a REMARC ancillary study analysing the impact of lenalidomide maintenance on the prognostic value of low NKCCs.
View Article and Find Full Text PDFArticle Synopsis
- Early identification of high-risk diffuse large B-cell lymphoma (DLBCL) patients is crucial for tailoring innovative treatments, as higher total metabolic tumor volume (TMTV) at baseline is linked to poorer survival outcomes.
- In a study analyzing patients aged 60-80 from the phase 3 REMARC trial, a TMTV cutoff of 220 cm³ was determined to aid in predicting progression-free survival (PFS) and overall survival (OS).
- The findings highlight that high TMTV, along with a poor Eastern Cooperative Oncology Group performance status (ECOG PS), can help identify an ultra-risk group, suggesting the need for more aggressive treatment strategies even after initial successful therapy with R-CHOP.
Objectives: To assess the reduction of transfusions rate in transfusion-dependent patients with low-risk myelodysplastic syndrome (MDS) with iron overload treated with deferasirox.
Methods: Prospective observational study. Primary endpoint was reduction in transfusion requirements (RTR) at 3 months, (assessed on 8-week period).
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
J Clin Oncol
August 2017
Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an immunomodulatory agent, has shown activity in DLBCL. This randomized phase III trial compared lenalidomide as maintenance therapy with placebo in elderly patients with DLBCL who achieved a complete response (CR) or partial response (PR) to R-CHOP induction.
View Article and Find Full Text PDF